Endeavors towards transformation of M. tuberculosis thymidylate kinase (MtbTMPK) inhibitors into potential antimycobacterial agents
作者:Yanlin Jian、Romain Merceron、Steven De Munck、He Eun Forbes、Fabian Hulpia、Martijn D.P. Risseeuw、Kristof Van Hecke、Savvas N. Savvides、Hélène Munier-Lehmann、Helena.I.M. Boshoff、Serge Van Calenbergh
DOI:10.1016/j.ejmech.2020.112659
日期:2020.11
As the last enzyme in nucleotide synthesis as precursors for DNA replication, thymidylate kinase of M. tuberculosis (MtbTMPK) attracts significant interest as a target in the discovery of new anti-tuberculosis agents. Earlier, we discovered potent MtbTMPK inhibitors, but these generally suffered from poor antimycobacterial activity, which we hypothesize is due to poor bacterial uptake. To address this
作为核苷酸合成中最后一种作为DNA复制前体的酶,结核分枝杆菌的胸苷酸激酶(Mtb TMPK)作为发现新型抗结核病药物的靶标引起了人们的极大兴趣。早些时候,我们发现了有效的Mtb TMPK抑制剂,但是这些通常都具有很差的抗分枝杆菌活性,我们认为这是由于细菌吸收差所致。为了解决这个问题,我们在此描述了为先前报道的Mtb TMPK抑制剂配备靶向部分以增加杂交类似物的全细胞活性的努力。引入简化的铁螯合铁载体基序产生了类似物17结合了良好的酶抑制活性和显着的抗结核分枝杆菌活性(MIC为12.5μM)。缀合的Mtb与咪唑并[1,2 TMPK抑制剂一个]吡啶或3,5-二硝基苯甲酰胺,得到的支架类似物26,27和28,具有中等的Mtb TMPK酶抑制效能,但对分枝杆菌亚微摩尔活性而无细胞毒性显著。这些结果表明,与已知有利于分枝杆菌吸收的结构基序结合可能是发现新的抗分枝杆菌药物的有效方法。